Skip to main content

Articles

Page 2 of 13

  1. Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton’s tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. However, many patients relapse post CAR-T therapy w...

    Authors: Fangfang Yan, Vivian Jiang, Alexa Jordan, Yuxuan Che, Yang Liu, Qingsong Cai, Yu Xue, Yijing Li, Joseph McIntosh, Zhihong Chen, Jovanny Vargas, Lei Nie, Yixin Yao, Heng-Huan Lee, Wei Wang, JohnNelson R. Bigcal…
    Citation: Experimental Hematology & Oncology 2024 13:14
    Content type: Research Published on:

  2. Glioblastoma multiforme (GBM) stands as a formidable challenge in oncology because of its aggressive nature and severely limited treatment options. Despite decades of research, the survival rates for GBM remai...

    Authors: Charles H. Williams, Leif R. Neitzel, Jessica Cornell, Samantha Rea, Ian Mills, Maya S. Silver, Jovanni D. Ahmad, Konstantin G. Birukov, Anna Birukova, Henry Brem, Betty Tyler, Eli E. Bar and Charles C. Hong
    Citation: Experimental Hematology & Oncology 2024 13:13
    Content type: Research Published on:

  3. Leukemias are refractory hematological malignancies, characterized by marked intrinsic heterogeneity which poses significant obstacles to effective treatment. However, traditional bulk sequencing techniques ha...

    Authors: Jianche Liu, Penglei Jiang, Zezhen Lu, Zebin Yu and Pengxu Qian
    Citation: Experimental Hematology & Oncology 2024 13:12
    Content type: Review Published on:

  4. KRAS mutation is one of the most common oncogenic drivers in NSCLC, however, the response to immunotherapy is heterogeneous owing to the distinct co-occurring genomic alterations. KRAS/LKB1 co-mutated lung adenoc...

    Authors: Meng Qiao, Fei Zhou, Xinyu Liu, Tao Jiang, Haowei Wang, Xuefei Li, Chao Zhao, Lei Cheng, Xiaoxia Chen, Shengxiang Ren, Zaiqi Wang and Caicun Zhou
    Citation: Experimental Hematology & Oncology 2024 13:11
    Content type: Research Published on:

  5. Metabolic reprogramming is an emerging hallmark of cancer cells, enabling them to meet increased nutrient and energy demands while withstanding the challenging microenvironment. Cancer cells can switch their m...

    Authors: Jianqiang Yang, Chloe Shay, Nabil F. Saba and Yong Teng
    Citation: Experimental Hematology & Oncology 2024 13:10
    Content type: Review Published on:

  6. t(8;21)(q22;q22) is one of the most frequent chromosomal abnormalities in acute myeloid leukemia (AML), leading to the generation of the fusion protein AML1-ETO. Despite t(8;21) AML being considered as a subty...

    Authors: Wei Zhou, Siying Li, Hong Wang, Jingfeng Zhou, Shuyi Li, Guofeng Chen, Wei Guan, Xianli Fu, Clara Nervi, Li Yu and Yonghui Li
    Citation: Experimental Hematology & Oncology 2024 13:9
    Content type: Research Published on:

  7. RNA modifications have been proven to play fundamental roles in regulating cellular biology process. Recently, maladjusted N7-methylguanosine (m7G) modification and its modifiers METTL1/WDR4 have been confirmed a...

    Authors: Pan Zhao, Lin Xia, Dan Chen, Wei Xu, Huanping Guo, Yinying Xu, Bingbing Yan, Xiao Wu, Yuxia Li, Yunfang Zhang and Xi Zhang
    Citation: Experimental Hematology & Oncology 2024 13:8
    Content type: Research Published on:

  9. Cancer immunotherapy has emerged as a promising strategy in the treatment of colorectal cancer, and relapse after tumor immunotherapy has attracted increasing attention. Cancer stem cells (CSCs), a small subse...

    Authors: Qi Zhao, Hong Zong, Pingping Zhu, Chang Su, Wenxue Tang, Zhenzhen Chen and Shuiling Jin
    Citation: Experimental Hematology & Oncology 2024 13:6
    Content type: Review Published on:

  10. Hepatocellular carcinoma (HCC) is one of the most common malignancies with a high lethality rate. ZMIZ2 is a transcriptional co-activator implicated in various human diseases. However, the role and molecular m...

    Authors: Yang Ding, Yumei Ning, Hui Kang, Yuan Yuan, Kun Lin, Chun Wang, Yun Yi, Jianghua He, Lurao Li, Xingxing He and Ying Chang
    Citation: Experimental Hematology & Oncology 2024 13:5
    Content type: Research Published on:

  11. From October 2017 to June 2022, we retrospectively report outcomes of R/R DLBCL patients with failure of CAR-T therapy, then receiving allo-HSCT. Among 10 patients, 5 were males and 5 females, with a median ag...

    Authors: Mengya Cong, Sicheng Ai, Liqing Kang, Mao Jin, Ying Zhu, Caixia Li, Zhengming Jin, Lei Yu, Depei Wu and Haiwen Huang
    Citation: Experimental Hematology & Oncology 2024 13:4
    Content type: Correspondence Published on:

  12. As integral components of the immune microenvironment, tissue resident macrophages (TRMs) represent a self-renewing and long-lived cell population that plays crucial roles in maintaining homeostasis, promoting...

    Authors: Minmin Cao, Zihao Wang, Wanying Lan, Binghua Xiang, Wenjun Liao, Jie Zhou, Xiaomeng Liu, Yiling Wang, Shichuan Zhang, Shun Lu, Jinyi Lang and Yue Zhao
    Citation: Experimental Hematology & Oncology 2024 13:3
    Content type: Review Published on:

  13. Biliary tract cancers (BTCs) are heterogeneous malignancies with dismal prognosis due to tumor aggressiveness and poor response to limited current therapeutic options. Tumor exome profiling has allowed to succ...

    Authors: Clémence Astier, Carine Ngo, Léo Colmet-Daage, Virginie Marty, Olivia Bawa, Claudio Nicotra, Maud Ngo-Camus, Antoine Italiano, Christophe Massard, Jean-Yves Scoazec, Cristina Smolenschi, Michel Ducreux, Antoine Hollebecque and Sophie Postel-Vinay
    Citation: Experimental Hematology & Oncology 2024 13:2
    Content type: Correspondence Published on:

  14. The use of central nervous system (CNS) prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) remains controversial. Although uncommon, CNS relapses are invariably fatal in this otherwise curable...

    Authors: Bernard Ji Guang Chua, Chen Ee Low, Chun En Yau, Ya Hwee Tan, Jianbang Chiang, Esther Wei Yin Chang, Jason Yongsheng Chan, Eileen Yi Ling Poon, Nagavalli Somasundaram, Mohamed Farid Bin Harunal Rashid, Miriam Tao, Soon Thye Lim and Valerie Shiwen Yang
    Citation: Experimental Hematology & Oncology 2024 13:1
    Content type: Review Published on:

  15. KRASG12C inhibitors (KRASG12Ci) AMG510 and MRTX849 have shown promising efficacy in clinical trials and been approved for the treatment of KRASG12C-mutant cancers. However, the emergence of therapy-related drug r...

    Authors: Yafang Wang, Mingyue Yao, Cheng Li, Kexin Yang, Xiaolong Qin, Lansong Xu, Shangxuan Shi, Chengcheng Yu, Xiangjun Meng and Chengying Xie
    Citation: Experimental Hematology & Oncology 2023 12:105
    Content type: Research Published on:

  16. Triple-Negative Breast Cancer is particularly aggressive, and its metastasis to the brain has a significant psychological impact on patients' quality of life, in addition to reducing survival. The development ...

    Authors: Julien Cicero, Sarah Trouvilliez, Martine Palma, Gaetan Ternier, Laurine Decoster, Eloise Happernegg, Nicolas Barois, Alexandre Van Outryve, Lucie Dehouck, Roland P. Bourette, Eric Adriaenssens, Chann Lagadec, Cagatay Mehmet Tarhan, Dominique Collard, Zied Souguir, Elodie Vandenhaute…
    Citation: Experimental Hematology & Oncology 2023 12:104
    Content type: Research Published on:

  17. Pyroptosis, an inflammatory programmed cell death, distinguishes itself from apoptosis and necroptosis and has drawn increasing attention. Recent studies have revealed a correlation between the expression leve...

    Authors: Mengyuan Li, Ping Jiang, Yuhan Yang, Liting Xiong, Shuhua Wei, Junjie Wang and Chunxiao Li
    Citation: Experimental Hematology & Oncology 2023 12:103
    Content type: Review Published on:

  18. Pseudomyxoma peritonei (PMP) is a rare disease characterized by a massive accumulation of mucus in the peritoneal cavity. The only effective treatment is aggressive surgery, aimed at removing all visible tumor...

    Authors: Mari C. Vázquez-Borrego, Melissa Granados-Rodríguez, Florina I. Bura, Ana Martínez-López, Blanca Rufián-Andújar, Francisca Valenzuela-Molina, Lidia Rodríguez-Ortiz, Sergio Haro-Yuste, Ana Moreno-Serrano, Rosa Ortega-Salas, Rafael Pineda-Reyes, Carmen Michán, José Alhama, Antonio Romero-Ruiz and Álvaro Arjona-Sánchez
    Citation: Experimental Hematology & Oncology 2023 12:102
    Content type: Correspondence Published on:

  19. Differentiating between pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) is crucial for the appropriate course of treatment, especially with advancements in the role of neoadjuvant chemothe...

    Authors: Mireia Mato Prado, Jisce R. Puik, Leandro Castellano, Elena López-Jiménez, Daniel S. K. Liu, Laura L. Meijer, Tessa Y. S. Le Large, Eleanor Rees, Niccola Funel, Shivan Sivakumar, Stephen P. Pereira, Geert Kazemier, Babs M. Zonderhuis, Joris I. Erdmann, Rutger-Jan Swijnenburg, Andrea Frilling…
    Citation: Experimental Hematology & Oncology 2023 12:101
    Content type: Correspondence Published on:

  20. Cyclic-dependent kinase (CDK) 4/6 kinases, as the critical drivers of the cell cycle, are involved in the tumor progression of various malignancies. Pharmacologic inhibitors of CDK4/6 have shown significant cl...

    Authors: Chuntao Quan, Zhijie Wu, Juan Xiong, Manqing Li, Yu Fu, Jiaying Su, Yue Wang, Lvwen Ning, Deju Zhang and Ni Xie
    Citation: Experimental Hematology & Oncology 2023 12:100
    Content type: Research Published on:

  21. Multiple myeloma (MM) is related to immune disorders, recent studys have revealed that immunotherapy can greatly benefit MM patients. Immune checkpoints can negatively modulate the immune system and are closel...

    Authors: Zhaoyun Liu, Xintong Xu, Hui Liu, Xianghong Zhao, Chun Yang and Rong Fu
    Citation: Experimental Hematology & Oncology 2023 12:99
    Content type: Review Published on:

  22. Natural killer (NK) cells are promising alternatives for the production of “off-the-shelf” CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells. We synthesized four single VHH-...

    Authors: Quan Ren, Yingling Zu, Hongchang Su, Qiumei Lu, Bin Xiang, Yanping Luo, Jishuai Zhang and Yongping Song
    Citation: Experimental Hematology & Oncology 2023 12:98
    Content type: Correspondence Published on:

  23. Dendritic cells (DCs) serve as a pivotal link connecting innate and adaptive immunity by processing tumor-derived antigens and activating T cells. The advent of single-cell sequencing has revolutionized the ca...

    Authors: Qingyu Huang, Fuhao Wang, Di Hao, Xinyu Li, Xiaohui Li, Tianyu Lei, Jinbo Yue and Chao Liu
    Citation: Experimental Hematology & Oncology 2023 12:97
    Content type: Review Published on:

  24. Being stimulated by the chemokine CXCL12, the CXCR4 / CXCR7 cascade is involved in tumor proliferation, migration, and metastasis. The interaction between CXCL12, secreted by cells from the microenvironment, a...

    Authors: Gamal A. Wakileh, Philipp Bierholz, Mara Kotthoff, Margaretha A. Skowron, Felix Bremmer, Alexa Stephan, Stephanie M. Anbuhl, Raimond Heukers, Martine J. Smit, Philipp Ströbel and Daniel Nettersheim
    Citation: Experimental Hematology & Oncology 2023 12:96
    Content type: Correspondence Published on:

  26. Recurrence is one of the main causes of treatment failure in early-stage non-small cell lung cancer (NSCLC). However, there are no predictors of the recurrence of early-stage NSCLC, and the molecular mechanism...

    Authors: Hao Luo, Qing Li, Ren-Tao Wang, Liang Zhang, Wei Zhang, Meng-Sheng Deng, Yuan-Yuan Luo, Xintong Ji, Yongheng Wen, Xuan-Rui Zhou, Bo Xu, Dong Wang, Bin Hu, Hua Jin and Cheng-Xiong Xu
    Citation: Experimental Hematology & Oncology 2023 12:94
    Content type: Research Published on:

  28. Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and ...

    Authors: Yuqin Song, Shang-Ju Wu, Zhixiang Shen, Donglu Zhao, Thomas Sau Yan Chan, Huiqiang Huang, Lugui Qiu, Jianyong Li, Tran-der Tan, Jun Zhu, Yongping Song, Wei-Han Huang, Weili Zhao, Herman Sung Yu Liu, Wei Xu, Naizhi Chen…
    Citation: Experimental Hematology & Oncology 2023 12:92
    Content type: Review Published on:

  29. Circular RNAs (circRNAs) are a class of covalently closed, endogenous ncRNAs. Most circRNAs are derived from exonic or intronic sequences by precursor RNA back-splicing. Advanced high-throughput RNA sequencing...

    Authors: Xin-Yi Feng, Shun-Xin Zhu, Ke-Jia Pu, Heng-Jing Huang, Yue-Qin Chen and Wen-Tao Wang
    Citation: Experimental Hematology & Oncology 2023 12:91
    Content type: Review Published on:

  30. CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies. However, 30%–60% of patients eventually...

    Authors: Jia Xu, Wenjing Luo, Chenggong Li and Heng Mei
    Citation: Experimental Hematology & Oncology 2023 12:90
    Content type: Review Published on:

  31. Impaired neutrophil activity is an important issue in chronic lymphocytic leukemia (CLL), as it contributes to a dysfunctional immune response leading to life-threatening infections in patients. Some features ...

    Authors: Agnieszka Goral, Marta Sledz, Aneta Manda-Handzlik, Adrianna Cieloch, Alicja Wojciechowska, Mieszko Lachota, Agnieszka Mroczek, Urszula Demkow, Radoslaw Zagozdzon, Katarzyna Matusik, Malgorzata Wachowska and Angelika Muchowicz
    Citation: Experimental Hematology & Oncology 2023 12:89
    Content type: Research Published on:

  32. CAR T cell therapy has been successfully used in the treatment of hematological malignancies, and the strategy that deletion of inhibitory receptor on the CAR T cell surface, such as PD-1, greatly enhance the ...

    Authors: Ming Liu, Linlin Zhang, Mingtian Zhong, Yihao Long, Wenhui Yang, Ting Liu, Xingxu Huang and Xiaodong Ma
    Citation: Experimental Hematology & Oncology 2023 12:88
    Content type: Correspondence Published on:

  33. Nucleophosmin (NPM1) is a widely expressed nucleocytoplasmic shuttling protein with prominent nucleolar localization. It is estimated that 25–35% of adult patients with acute myeloid leukemia (AML) carry NPM1 mut...

    Authors: Yiyi Yao, Xiangjie Lin, Chen Wang, Ying Gu, Jie Jin, Yinghui Zhu and Huafeng Wang
    Citation: Experimental Hematology & Oncology 2023 12:87
    Content type: Correspondence Published on:

  35. Immunosuppression induced by programmed cell death protein 1 (PD1) presents a significant constraint on the effectiveness of chimeric antigen receptor (CAR)-T therapy. The potential of combining PD1/PDL1 (Prog...

    Authors: Ang Zhang, Shenyu Wang, Yao Sun, Yikun Zhang, Long Zhao, Yang Yang, Yijian Zhang, Lei Xu, Yangyang Lei, Jie Du, Hu Chen, Lian Duan, Mingyi He, Lintao Shi, Lei Liu, Quanjun Wang…
    Citation: Experimental Hematology & Oncology 2023 12:85
    Content type: Research Published on:

  37. Focal adhesion kinase (FAK), a nonreceptor cytoplasmic tyrosine kinase, is a vital participant in primary cellular functions, such as proliferation, survival, migration, and invasion. In addition, FAK regulate...

    Authors: Ximin Tan, Yuheng Yan, Bin Song, Shuangli Zhu, Qi Mei and Kongming Wu
    Citation: Experimental Hematology & Oncology 2023 12:83
    Content type: Review Published on:

  38. The pattern recognition receptor long pentraxin-3 (PTX3) plays conflicting roles in cancer by acting as an oncosuppressor or as a pro-tumor mediator depending on tumor context. Triple negative breast cancer (T...

    Authors: Arianna Giacomini, Marta Turati, Elisabetta Grillo, Sara Rezzola, Gaia Cristina Ghedini, Ander Churruca Schuind, Eleonora Foglio, Federica Maccarinelli, Jessica Faletti, Serena Filiberti, Angela Chambery, Mariangela Valletta, Laura Melocchi, Stephanie Gofflot, Barbara Chiavarina, Andrei Turtoi…
    Citation: Experimental Hematology & Oncology 2023 12:82
    Content type: Research Published on:

  39. In KMT2A-rearranged acute lymphoblastic leukemia (ALL), an aggressive malignancy, oncogenic KMT2A-fusion proteins inappropriately recruit DOT1L to promote leukemogenesis, highlighting DOT1L as an attractive thera...

    Authors: Pauline Schneider, Nicholas T. Crump, Susan T.C.J.M. Arentsen-Peters, Alastair L. Smith, Rico Hagelaar, Fabienne R.S. Adriaanse, Romy S. Bos, Anja de Jong, Stefan Nierkens, Bianca Koopmans, Thomas A. Milne, Rob Pieters and Ronald W. Stam
    Citation: Experimental Hematology & Oncology 2023 12:81
    Content type: Research Published on:

  40. Prostate cancer (PC) is one of the most common cancers in males and the fifth leading reason of death. Age, ethnicity, family history, and genetic defects are major factors that determine the aggressiveness an...

    Authors: Ganji Lakshmi Varaprasad, Vivek Kumar Gupta, Kiran Prasad, Eunsu Kim, Mandava Bhuvan Tej, Pratik Mohanty, Henu Kumar Verma, Ganji Seeta Rama Raju, LVKS Bhaskar and Yun Suk Huh
    Citation: Experimental Hematology & Oncology 2023 12:80
    Content type: Research Published on:

  41. Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma subtype which remains incurable despite multimodal approach including chemoimmunotherapy followed by stem cell transplant, targeted approaches s...

    Authors: Wing Keung Chan, Jessica Williams, Kinnari Sorathia, Betsy Pray, Kaled Abusaleh, Zehua Bian, Archisha Sharma, Ian Hout, Shamama Nishat, Walter Hanel, Shelby L. Sloan, Aneeq Yasin, Nathan Denlinger, Xiaoli Zhang, Natarajan Muthusamy, Sumithira Vasu…
    Citation: Experimental Hematology & Oncology 2023 12:79
    Content type: Research Published on:

  42. Leiomyosarcoma (LMS) is a rare soft tissue sarcoma (STS) that begins in smooth muscle tissue and most often initiates in the abdomen or uterus. Compared with other uterine cancers, uterine LMS (ULMS) is an agg...

    Authors: Sonam Mittal, Ishaque Pulikkal Kadamberi, Hua Chang, Feng Wang, Sudhir Kumar, Shirng-Wern Tsaih, Christopher J. Walker, Pradeep Chaluvally-Raghavan, John Charlson, Yosef Landesman and Sunila Pradeep
    Citation: Experimental Hematology & Oncology 2023 12:78
    Content type: Correspondence Published on:

  43. UTX (encoded by KDM6A), a histone demethylase for H3K27me2/3, is frequently mutated in human cancers. However, its functional and regulatory mechanisms in colorectal cancer (CRC) remain unclear.

    Authors: Dakui Luo, Min Chen, Qingguo Li, Kangjunjie Wang, Kaihua Wang, Junqiang Li, Guoxiang Fu, Zezhi Shan, Qi Liu, Yufei Yang, Lei Liang, Yanlei Ma, Yi Qin, Jun Qin, Daming Gao and Xinxiang Li
    Citation: Experimental Hematology & Oncology 2023 12:77
    Content type: Research Published on:

  44. T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic tumor, characterized by several genetic alterations, that constitutes 15% of pediatric and 25% of adult ALL. While with current therapeutic protocol...

    Authors: Sonia Minuzzo, Valentina Agnusdei, Marica Pinazza, Adriana A. Amaro, Valeria Sacchetto, Ulrich Pfeffer, Roberta Bertorelle, Orietta Spinelli, Valentina Serafin and Stefano Indraccolo
    Citation: Experimental Hematology & Oncology 2023 12:76
    Content type: Correspondence Published on:

  45. The mechanisms underlying the occurrence and development of esophageal squamous cell carcinoma (ESCC) remains to be elucidated. The present study aims to investigate the roles and implications of IGF2BP1 overe...

    Authors: Juan-Juan Wang, Ding-Xiong Chen, Yu Zhang, Xin Xu, Yan Cai, Wen-Qiang Wei, Jia-Jie Hao and Ming-Rong Wang
    Citation: Experimental Hematology & Oncology 2023 12:75
    Content type: Research Published on:

  46. Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing nu...

    Authors: Jiangxue Hou, Yufu Li and Quande Lin
    Citation: Experimental Hematology & Oncology 2023 12:74
    Content type: Correspondence Published on:

    The Correction to this article has been published in Experimental Hematology & Oncology 2023 12:86

  47. Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising advances in cancer treatment. It is based on genetically modified T cells to express a CAR, which enables the recognition of the spec...

    Authors: Cristina Aparicio, Carlos Acebal and Margarita González-Vallinas
    Citation: Experimental Hematology & Oncology 2023 12:73
    Content type: Review Published on:

  48. Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse. For several decades, the standard treatment s...

    Authors: Tingxun Lu, Jie Zhang, Zijun Y. Xu-Monette and Ken H. Young
    Citation: Experimental Hematology & Oncology 2023 12:72
    Content type: Review Published on:

  49. Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (P...

    Authors: Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, Maria Labrador, Monica Maccagno, Michela Cumerlato, Federico Oreglia, Lorenzo Prever, Veronica Manicardi, Elisa Taiana, Domenica Ronchetti, Mattia D’Agostino, Francesca Gay, Alessandra Larocca, Lenka Besse, Giorgio Roberto Merlo…
    Citation: Experimental Hematology & Oncology 2023 12:71
    Content type: Research Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 9.4
    5-year Journal Impact Factor: 8.3
    Source Normalized Impact per Paper (SNIP): 1.583
    SCImago Journal Rank (SJR): 2.384

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 100

    Usage 2023
    Downloads: 696,150
    Altmetric mentions: 375

On the blog

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us